


PHARMACEUTICAL 2022



eFFECTOR Therapeutics Inc. Rank 29 of 475





PHARMACEUTICAL 2022



eFFECTOR Therapeutics Inc. Rank 29 of 475



The relative strengths and weaknesses of eFFECTOR Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of eFFECTOR Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 511% points. The greatest weakness of eFFECTOR Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 460% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	52,896
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,978
Liabilities, Non-Current	126
Other Assets	1,069
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	32,668
Other Net Income	47,695
Property and Equipment	91
Research and Development	19,956
Revenues	1,430
Selling, General and Administrative Expense	13,371

Output Variable	Value in 1000 USD
Assets	54,056
Liabilities	36,772
Expenses	33,327
Stockholders Equity	17,284
Net Income	15,798
Comprehensive Net Income	15,798
Economic Capital Ratio	183%